Cargando…

Nilotinib-Induced Immune-Mediated Liver Injury: Corticosteroid as a Possible Therapeutic Option

Introduction: Nilotinib is a BCR-ABL tyrosine kinase inhibitor approved for chronic myeloid leukemia. We present a case of severe immune-mediated liver injury by nilotinib treatment. Case report: A 59-year-old woman was referred to the liver clinic because of elevated liver enzyme levels. One year p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Hyun, Sung, Pil Soo, Jung, Eun Sun, Cho, Sungwoo, Bae, Si Hyun, Kim, Dong-Wook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367179/ https://www.ncbi.nlm.nih.gov/pubmed/32754445 http://dx.doi.org/10.3389/fonc.2020.01160

Ejemplares similares

A Case of Severe, Nilotinib-Induced Liver Injury
por: Belopolsky, Yuliya, et al.
Publicado: (2019)

Nilotinib-induced liver injury: A case report
por: Tan, Youwen, et al.
Publicado: (2020)

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
por: Hochhaus, Andreas, et al.
Publicado: (2015)

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
por: Martinelli, Giovanni, et al.
Publicado: (2007)

Nilotinib for the Frontline Treatment of Chronic Myeloid Leukemia Carrying the p230 Transcript: Dream or Reality?
por: Capuozzo, Maurizio, et al.
Publicado: (2014)

Possible Therapeutic Options for Complex Regional Pain Syndrome
por: Cha, Myeounghoon, et al.
Publicado: (2021)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection
por: Sung, Pil Soo, et al.
Publicado: (2020)

Coumarins and Gastrointestinal Cancer: A New Therapeutic Option?
por: Banikazemi, Zarrin, et al.
Publicado: (2021)

Molecular Network of Colorectal Cancer and Current Therapeutic Options
por: Huang, Zhe, et al.
Publicado: (2022)

Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case Report
por: Capodanno, Isabella, et al.
Publicado: (2021)

Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib
por: Loscocco, Federica, et al.
Publicado: (2021)

Intrahepatic infiltration of activated CD8(+) T cells and mononuclear phagocyte is associated with idiosyncratic drug-induced liver injury
por: Yang, Hyun, et al.
Publicado: (2023)

Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy
por: Sung, Pil Soo, et al.
Publicado: (2020)

Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor
por: Fujisawa, Yasuhiro, et al.
Publicado: (2018)

Corrigendum: Intrahepatic infiltration of activated CD8(+) T cells and mononuclear phagocyte is associated with idiosyncratic drug-induced liver injury
por: Yang, Hyun, et al.
Publicado: (2023)

Exosomal miR-125b Exerts Anti-Metastatic Properties and Predicts Early Metastasis of Hepatocellular Carcinoma
por: Kim, Hye Seon, et al.
Publicado: (2021)

Dysplastic Nevus with Eruptive Melanocytic Lesions That Developed during Nilotinib Therapy for Chronic Myeloid Leukemia
por: Lee, Joo Hyun, et al.
Publicado: (2015)

Liver-Directed Treatment Options Following Liver Tumor Recurrence: A Review of the Literature
por: Aquina, Christopher T., et al.
Publicado: (2022)

The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer
por: Zhang, Chunye, et al.
Publicado: (2020)

Application of systemic treatment in conversion therapy options for liver cancer
por: Bei, Haoyang, et al.
Publicado: (2022)

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings
por: Cheng, Fang, et al.
Publicado: (2023)

Anti-fibrotic effects of branched-chain amino acids on hepatic stellate cells
por: Lee, Hae Lim, et al.
Publicado: (2022)

Sustained-Release Corticosteroid Options
por: Cabrera, Mariana, et al.
Publicado: (2014)

Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)
por: Sicuranza, Anna, et al.
Publicado: (2022)

Editorial: Cancer stem cell differentiation: A realistic potential therapeutic option?
por: Buccarelli, Mariachiara, et al.
Publicado: (2023)

Nilotinib-Associated Destructive Thyroiditis
por: Bakerywala, Suhalia, et al.
Publicado: (2015)

Nilotinib-Induced Keratosis Pilaris
por: Leong, Wai Mun Sean, et al.
Publicado: (2016)

A Unique Immune-Related Gene Signature Represents Advanced Liver Fibrosis and Reveals Potential Therapeutic Targets
por: Sung, Pil-Soo, et al.
Publicado: (2022)

Vitamin D: Possible Therapeutic Roles in Hepatocellular Carcinoma
por: Adelani, Isaacson B., et al.
Publicado: (2021)

RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?
por: Sartorius, Kurt, et al.
Publicado: (2022)

KDM4 Involvement in Breast Cancer and Possible Therapeutic Approaches
por: Varghese, Benluvankar, et al.
Publicado: (2021)

Management of Cancer Cachexia: Attempting to Develop New Pharmacological Agents for New Effective Therapeutic Options
por: Marceca, Gioacchino P., et al.
Publicado: (2020)

Regulation of Hedgehog Signaling by miRNAs and Nanoformulations: A Possible Therapeutic Solution for Colorectal Cancer
por: Javed, Zeeshan, et al.
Publicado: (2021)

Acitretin as a Therapeutic Option for Chronic Hand Eczema
por: Song, Margaret, et al.
Publicado: (2017)

Nilotinib based pharmacophore models for BCRABL
por: Sabitha, Kesavan
Publicado: (2012)

Nilotinib – Differentiating the Hope from the Hype
por: Wyse, Richard K., et al.
Publicado: (2016)

Hemorheological Alteration in Patients Clinically Diagnosed with Chronic Liver Diseases
por: Jang, Bohyun, et al.
Publicado: (2016)

Tumor-Specific Induction of the Intrinsic Apoptotic Pathway—A New Therapeutic Option for Advanced Prostate Cancer?
por: Wolf, Philipp
Publicado: (2019)

Phyto-Immunotherapy, a Complementary Therapeutic Option to Decrease Metastasis and Attack Breast Cancer Stem Cells
por: Fiorentino, Susana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7378g493siulrbjkgdl8msbjh6